Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma
Melanoma is a disease process which has been increasing in incidence over the past three decades and metastatic melanoma carries a poor prognosis. Through genetic studies of this disease, it has been determined that the BRAF V600 mutation plays a major role in the pathophysiology of the disease and...
Saved in:
Main Authors: | Brenen P. Swofford, Jade Homsi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Case Reports in Oncological Medicine |
Online Access: | http://dx.doi.org/10.1155/2017/8241624 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation
by: K. Sahadudheen, et al.
Published: (2016-01-01) -
Progress in immunotherapy for brain metastatic melanoma
by: Shicheng Zheng, et al.
Published: (2025-01-01) -
Fulminant Disseminated Intravascular Coagulation as Initial Presentation of BRAF-Mutated Melanoma
by: Jeremy Chuang, et al.
Published: (2019-01-01) -
RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
by: Jiannan Yao, et al.
Published: (2018-01-01) -
Pharmacokinetic Evaluation of [C]CEP-32496 in Nude Mice Bearing BRAF Mutation-Induced Melanomas
by: Cuiping Jiang MMSc, et al.
Published: (2018-09-01)